Equillium
Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and immuno-inflammatory disorders with high unmet medical need. Its lead candidate, EQ001 (Itolizumab), is a first-in-class monoclonal antibody that selectively targets the CD6 immune receptor to downregulate pathogenic effector T cells while preserving regulatory T cells by modulating the CD6-ALCAM signaling pathway. The approach targets a range of immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. Equillium aims to advance its programs through clinical development and may commercialize products independently or through partnerships or strategic transactions to monetize its pipeline.
2 past transactions
Bioniz Therapeutics
Acquisition in 2022
Bioniz Therapeutics, Inc. is a biopharmaceutical company based in Irvine, California, established in 2009. It specializes in discovering and developing innovative peptide therapeutics aimed at treating immune diseases and cancer. The company's pipeline includes BNZ-1, a selective inhibitor targeting interleukin cytokines IL2, IL9, and IL15, which are significant contributors to conditions such as HTLV-1 Associated Myelopathy and T-cell leukemias. Additionally, Bioniz is developing IL-15 and IL-21 inhibitors, as well as BNZ-3, an early-stage asset focused on inhibiting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics is committed to advancing its lead technologies through proof of concept and preclinical studies, with the goal of partnering for clinical trials and eventual commercialization.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.